Ensysce Biosciences, Inc.
7946 Ivanhoe Avenue, Suite 201
La Jolla, California 92037
May 9, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Attention: Lauren Sprague Hamill, Esq.
| Re: | Ensysce Biosciences, Inc. | |
| Registration Statement on Form S-3 | ||
| SEC File No. 333-286943 | ||
| Filed May 2, 2025 |
Ladies and Gentlemen:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. hereby requests that the effective date of the above-referenced Registration Statement be accelerated to 4:00 PM, Eastern Time, on May 9, 2025, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Locke LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Locke LLP, by calling Eric D. Kline at (412) 454-5046 or Gregory Rubis at (609) 951-4105.
Please direct any questions or comments concerning this request to Eric Kline or Gregory Rubis.
| ENSYSCE BIOSCIENCES, Inc. | ||
| By: | /s/ Lynn Kirkpatrick | |
| Name: | Dr. Lynn Kirkpatrick | |
| Title: | President and Chief Executive Officer | |
| cc: | Eric D. Kline, Troutman Pepper Locke LLP |
| Gregory Rubis, Troutman Pepper Locke LLP |